ICMR to start national sero surveys to assess COVID-19 spread: Health ministry

The Centre underlined that breaking the chain of transmission ensures lesser strain on the health infrastructure and better quality of care.

PTI
June 11, 2021 / 07:10 PM IST

The ICMR will start national-level sero surveys to assess the spread of COVID-19 and all states/UTs should also be encouraged to conduct them so that information from all geographies can be collected, the Union health ministry said on Friday. The ministry also said that the Covid situation in the country appears to be stabilising, but urged people to continue following the appropriate behaviour and social distancing norms.

The Indian Council of Medical Research (ICMR) will conduct national sero surveys to assess the Covid spread and states/UTs should also conduct them to get all geographies' information, it said.

The ministry said almost 78 percent decline in daily new COVID-19 cases has been noted in India since the highest reported peak in daily cases on May 7.

It also said that there has been 74 percent decrease in weekly COVID-19 positivity rate since the highest such rate was reported between April 30-May 6 at 21.6 percent.

The Centre underlined that breaking the chain of transmission ensures lesser strain on the health infrastructure and better quality of care.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

On the US's Food and Drug Administration (FDA) denying Emergency Use Authorisation (EUA) to Bharat Biotech's COVID-19 vaccine Covaxin, the health ministry said, We respect each country's regulatory system, but it will have no impact on India's vaccine programme.

Follow our full coverage of the coronavirus pandemic here.
PTI
TAGS: #coronavirus #Current Affairs #Health Ministry #ICMR #India #Indian Council of Medical Research #Sero Survey
first published: Jun 11, 2021 07:08 pm